Dr. Mohamed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
500 W Thomas Rd
Ste 300A
Phoenix, AZ 85013Phone+1 602-406-4000Fax+1 602-406-6498- Is this information wrong?
Education & Training
Yale-New Haven Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2013- Yale-New Haven Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2011
Norwalk Hospital/Yale UniversityFellowship, Pulmonary Disease, 2011 - 2013
University of Nevada Reno School of MedicineResidency, Internal Medicine, 2006 - 2009
University of Tripoli School of MedicineClass of 1995
Certifications & Licensure
AZ State Medical License 2019 - 2026
NV State Medical License 2009 - 2021
WV State Medical License 2015 - 2021
VA State Medical License 2014 - 2020
NM State Medical License 2007 - 2008- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
Publications & Presentations
PubMed
- 11 citationsBronchopleural Fistula as a Complication in a COVID-19 Patient Managed With Endobronchial ValvesAndrew Talon, Muhammad Arif, Hesham Mohamed, Abid Khokar, Ali Saeed> ;Journal of Investigative Medicine High Impact Case Reports. 2021 Apr 30
- 3 citationsTransjugular Intrahepatic Portosystemic Shunt (TIPS) in Refractory Transudative Chylothorax due to Liver CirrhosisMuhammad Farhan Khaliq, Muhammad Muslim Noorani, Monica Chowdhry, Hesham Mohamed, Ashish Koirala> ;Case Reports in Medicine. 2020 Feb 7
- Pulmonary Langerhans Cell Histiocytosis Associated with Bronchogenic Carcinoma.Muhammad Farhan Khaliq, Muhammad Muslim Noorani, Syed Maaz Tariq, Ashish Koirala, Hesham Mohamed> ;Cureus. 2020 Jan 12
- Join now to see all
Abstracts/Posters
- Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...Hesham Mohamed, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...Hesham Mohamed, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hospital Affiliations
St. Joseph's Hospital and Medical CenterPhoenix, Arizona
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
